Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 4/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 5/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954449 | 0.87 | HRH3 (0.47) | HRH3APPHAO1PTGES2PTGES | |
| SCHEMBL31257842 | 0.82 | APP (0.34) | APPMAPTKMT2AATM | |
| SCHEMBL1571249 | 0.82 | ASIC3 (0.44) | APPHAO1PTGES2MAPTKMT2A | |
| SCHEMBL9694697 | 0.78 | GRM5 (0.45) | HRH3HAO1PTGES2MAPTKMT2A | |
| SCHEMBL13597759 | 0.76 | HRH3 (0.41) | HRH3APPHAO1PTGES2DRD5 | |
| SCHEMBL20717544 | 0.76 | APP (0.59) | HRH3APPHAO1PTGES2MAPT | |
| SCHEMBL507497 | 0.76 | KIF11 (0.48) | HRH3 | |
| SCHEMBL22881118 | 0.76 | HRH3 (0.41) | HRH3HAO1PTGES2PTGESALOX5 | |
| SCHEMBL23135750 | 0.76 | PTPN11 (0.32) | HRH3CYP2D6HRH4 | |
| SCHEMBL4379793 | 0.76 | APP (0.48) | HRH3APPHAO1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | HRH3 3382/4885APP 1690/4885HAO1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.